Search
Erdafitinib
go.drugbank.com/drugs/DB12147ApprovedInvestigationalIn early April of 2019, the US FDA approved Janssen Pharmaceutical Companies' brand name Balversa (erdafitinib) as the first-ever fibroblast growth factor receptor (FGFR) kinase inhibitor indicated for patients with locally advanced or m...
Ferric oxide
go.drugbank.com/drugs/DB11576ApprovedInvestigationalIron(III) oxide or ferric oxide is the inorganic compound with the formula Fe2O3. It is one of the three main oxides of iron, the other two being iron(II) oxide (FeO) the rarer form, and iron(II,III) oxide (Fe3O4) which naturally as magn...
Mixtures: Aloe Vera CalamineAUTO3
go.drugbank.com/drugs/DB17364InvestigationalAUTO3 is bicistronic chimeric antigen receptor T-cell therapy investigated for acute lymphoblastic leukemia (ALL).
Talarozole
go.drugbank.com/drugs/DB13083InvestigationalTalarozole has been investigated for the treatment of Psoriasis and Cutaneous Inflammation.
Regramostim
go.drugbank.com/drugs/DB05386InvestigationalEndothelial cells and fibroblasts can also produce GM-CSF after exposure to TNF-α, IL-1, IL-2 and IFN-γ. GM-CSF is found associated with extracellular matrix and in membrane-bound formats too.
Efineptakin alfa
go.drugbank.com/drugs/DB16395InvestigationalCompared to endogenous IL-7, NT-I7 is more stable and potent, has a longer half-life, and has better bioavailability. … Efineptakin alfa (also known as NT-I7) is a long-acting human interleukin-7 (IL-7) fusion protein that promotes T-cell development, contributing to the immune response.
Synonyms: Recombinant human IL-7-HYFCGlutathione
go.drugbank.com/drugs/DB00143ApprovedInvestigationalNutraceuticalA tripeptide with many roles in cells. It conjugates to drugs to make them more soluble for excretion, is a cofactor for some enzymes, is involved in protein disulfide bond rearrangement and reduces peroxides.
Mixtures: OilOxycodegol
go.drugbank.com/drugs/DB14146InvestigationalLoxicodegol was developed by Nektar Therapeutics as an opioid analgesic with low abuse potential for the treatment of chronic pain . The lack of abuse potential is believed to be due to the drug's slow rate of entry into brain, a unique ...
Belnacasan
go.drugbank.com/drugs/DB05507InvestigationalVX-765 is the orally available prodrug of a potent and selective competitive inhibitor of ICE/caspase-1 (VRT-043198). VX-765 is currently under clinical development for the treatment of inflammatory and autoimmune conditions, as it block...
CG7870
go.drugbank.com/drugs/DB04981InvestigationalCG7870 is an oncolytic virus therapy for prostate cancer. It is a replication-selective, prostate-specific antigen-targeted oncolytic adenovirus, for the treatment of hormone-refractory, metastatic prostate cancer.